Animalcare trading statement highlights recent growth

Animalcare has seen a five percent year-on-year growth in sales during the 12 months ending on June 30th 2011.

The animal health company has published a pre-close trading update which highlights a strong performance from its fluid therapy and database service offerings in the last year, while the four new products launched in 2010-11 have also sold well.

"Earnings from continuing operations will again show a good progression from the same period last year and are expected to be in line with market expectations," it said.

Additionally, the firm stated that it is making plans to accommodate pharmaceutical contract manufacturing group Recipharm's plan to close its Ashton facility, which produces the 1ml ampoule version of Animalcare's product Buprecare.

Animalcare states that the measures it is taking will bring the impact of this supply disruption to a minimum level.

Last week, the company appointed director of marketing Dr Iain Menneer as a member of its board, allowing it to benefit from his input at a higher level.